Profile of:

Pal Géher

1975. University of Semmelweis - MD 1979 Specialization rheumatology and physiotherapy 1988 Phd (Social and medical consequences of AS) 2002-2020 Prof.of Rheumatology, Semmelweis Univ. 2020- Medical Director (Hospitaller Brothers of St. John of God, Budapest)

Full name: Pal Géher

Current country: Hungary

Membership level: Full

Type of membership: Member

Number of publications: 23

ASAS-EULAR recommandations for management of axial spondyloarthritis: 2022 update (2023)

Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study (2021)

Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study (2021)

Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial Spondyloarthritis (2021)

An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS (2018)

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis (2017)

Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe (2016)

Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages (2016)

Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis (2014)

Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study (2013)

Nonsteroidal antiinflammatory drug intake according to the Assessment of SpondyloArthritis International Society Score in clinical trials evaluating tumor necrosis factor blockers: example of etanercept in advanced ankylosing spondylitis (2012)

Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study (2012)

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis (2011)

Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE) (2011)

Development of a core set of domains for data collection in cohorts of patients with ankylosing spondylitis receiving anti-tumor necrosis factor-alpha therapy (2008)

ASAS/EULAR recommendations for the management of ankylosing spondylitis (2006)

[The role of biologic agents in the therapy of ankylosing spondylitis] (2006)

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis (2006)

[Hungarian adaptation of a disease-specific quality-of-life questionnaire in patients with ankylosing spondylitis] (2002)

Repeated cyclosporine therapy of peripheral arthritis associated with ankylosing spondylitis (2001)

Cardiac and cardiopulmonary disorders in patients with ankylosing spondylitis and rheumatoid arthritis (1988)

[Cardiac changes found in patients with ankylosing spondylarthritis] (1985)

HLA-B27-associated spondylarthritis in chronic brucellosis (1978)